At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PDAC Peridot Acquisition Corp
Not Yet Opened 08-10 16:00:00 EDT
11.23
+0.00
0.00%
| High11.23 | Low11.23 | Vol0.00 |
| Open11.23 | D1 Closing11.23 | Amplitude0.00% |
| Mkt Cap421.13M | Tradable Cap290.26M | Total Shares37.50M |
| T/O0.00 | T/O Rate0.00% | Tradable Shares25.85M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
GlobeNewswire · 2023-02-14
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
Canpipe Exhibiting at Booth 6526N, PDAC 2023 Convention in Toronto, March 5-8
StreetInsider · 2023-02-13
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
GlobeNewswire · 2023-02-02
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
Investor Opportunity to Meet Forum Energy Metals Management at The VRIC & PDAC Convention
StreetInsider · 2023-01-27
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
GlobeNewswire · 2023-01-10
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
PR Newswire · 2023-01-04
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
GlobeNewswire · 2023-01-03
BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event
PR Newswire · 2022-11-28
BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event
PDAC 2023 Awards Recognize Five Outstanding Industry Leaders
Financial Post · 2022-11-23
BioLineRx to Report Third Quarter 2022 Results on November 15, 2022
PR Newswire · 2022-11-10
BioLineRx to Report Third Quarter 2022 Results on November 15, 2022
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
PR Newswire · 2022-11-10
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
Purple Biotech to Present at the Jefferies London Healthcare Conference
GlobeNewswire · 2022-11-10
Purple Biotech Reports Third Quarter 2022 Financial Results
GlobeNewswire · 2022-11-08
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
PR Newswire · 2022-11-07
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
GlobeNewswire · 2022-11-02
Press Release: Third Quarter Update 2022
Dow Jones · 2022-10-24
BMF-219 Enters the Clinic for KRAS Solid Tumors
GlobeNewswire · 2022-10-14
BMF-219 Enters the Clinic for KRAS Solid Tumors
Press Release: RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology; Michael Lee-Chin appointed to the board of the company
Dow Jones · 2022-10-07
Introduction
Company Name.
Peridot Acquisition Corp
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Peridot Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, recapitalization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Houston, Texas.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App